Gilead Sciences has agreed to acquire biotechnology firm Arcellx in a transaction valued at about $7.8 billion, aiming to expand its cell therapy capabilities for cancer treatment. Under the agreement, Gilead will pay $115 per share in cash plus a $5 per share contingent value right, linked to future sales milestones of the therapy anitocabtagene autoleucel.
The companies already collaborate through Kite Pharma, a Gilead subsidiary, to develop and commercialize the investigational therapy anitocabtagene autoleucel, a BCMA-directed CAR T-cell therapy designed for patients with relapsed or refractory multiple myeloma. Clinical studies have shown strong and durable responses along with a manageable safety profile. A biologics license application for the treatment as a fourth-line therapy has been accepted by the U.S. Food and Drug Administration, with a regulatory decision expected on December 23, 2026.
Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences, stated, “This agreement reflects our conviction in the potential of anito-cel and our intention to move with speed so we can make the most of that potential for patients with multiple myeloma.” Beyond the therapy itself, Arcellx’s D-Domain CAR technology platform may support the development of next-generation cell therapies and bispecific treatments.
Rami Elghandour, Chairman and Chief Executive Officer of Arcellx, noted, “We are fortunate to have found a world-class partner in Gilead, which has the expertise to carry forward Arcellx’s legacy. Kite is well-positioned to maximize access to anito-cel, benefiting more patients, and the company’s commitment to be the leader in cell therapy.” The Boards of both companies have approved the deal, which is expected to close in the second quarter of 2026, pending regulatory clearance and other conditions.
